Cozzi-Lepri A
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, London, UK.
HIV Med. 2008 Jan;9(1):27-40. doi: 10.1111/j.1468-1293.2008.00523.x.
To investigate the concordance between any of the results of nine HIV-1 drug-resistance interpretation systems (ISs) and their ability to predict week 8 and week 24 virological responses to abacavir-containing combination therapy.
A total of 1306 HIV-infected patients with a viral load >500 HIV-1 RNA copies/mL and a baseline genotypic resistance test were included in the study. Predicted abacavir susceptibilities according to each rule-based IS were compared. Linear and logistic regressions were used to assess the prognostic value of each IS for week 8 and week 24 responses, respectively.
A median of three (interquartile range 1-5) abacavir mutations were detected at baseline. Comparing the IS predictions for abacavir susceptibility, 9% to 45% of patients were predicted to have resistant (R) virus, 9% to 53% virus with intermediate (I) resistance, and 23% to 74% susceptible (S) virus. Overall, the median week 8 viral load reduction was 1.61 log(10) copies/mL (95% confidence interval 1.52-1.71) and 50% of patients experienced virological failure at 24 weeks. Most ISs showed better virological responses with S and I viruses than with R viruses.
Despite some degree of variability in predicted abacavir susceptibility among ISs, most ISs are useful to predict virological response.
研究9种HIV-1耐药性解读系统(ISs)的任何结果之间的一致性,以及它们预测含阿巴卡韦联合治疗第8周和第24周病毒学反应的能力。
共有1306例HIV感染患者纳入研究,这些患者病毒载量>500 HIV-1 RNA拷贝/mL且进行了基线基因型耐药性检测。比较根据每个基于规则的IS预测的阿巴卡韦敏感性。分别使用线性回归和逻辑回归评估每个IS对第8周和第24周反应的预后价值。
基线时检测到的阿巴卡韦突变中位数为3个(四分位间距1-5)。比较IS对阿巴卡韦敏感性的预测,9%至45%的患者被预测为有耐药(R)病毒,9%至53%为有中度(I)耐药病毒,23%至74%为敏感(S)病毒。总体而言,第8周病毒载量降低中位数为1.61 log(10)拷贝/mL(95%置信区间1.52-1.71),50%的患者在24周时出现病毒学失败。大多数IS对S和I病毒显示出比R病毒更好的病毒学反应。
尽管各IS在预测阿巴卡韦敏感性方面存在一定程度的差异,但大多数IS对预测病毒学反应有用。